MDNA
Income statement / Annual
Last year (2023), Medicenna Therapeutics Corp.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Medicenna Therapeutics Corp.'s net income was $1.55 M.
See Medicenna Therapeutics Corp.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
03/31/2017 |
03/31/2016 |
03/31/2015 |
03/31/2014 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$9.30 M
|
$14.72 M
|
$10.87 M
|
$5.87 M
|
$3.02 M
|
$5.09 M
|
$4.23 M
|
$771.41 K
|
$766.30
|
$860.96
|
| General & Administrative Expenses |
$6.99 M
|
$7.72 M
|
$6.49 M
|
$2.49 M
|
$2.21 M
|
$3.00 M
|
$4.02 M
|
$469.71 K
|
$253.11
|
$112.62
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$6.99 M
|
$7.72 M
|
$6.49 M
|
$2.49 M
|
$2.21 M
|
$3.00 M
|
$4.02 M
|
$469.71 K
|
$253.11
|
$112.62
|
| Other Expenses |
$5.00 K
|
$37.00 K
|
$40.00 K
|
-$117.48 K
|
-$499.37 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$16.30 M
|
$22.47 M
|
$17.40 M
|
$8.24 M
|
$4.73 M
|
$7.42 M
|
$7.70 M
|
$1.20 M
|
$833.31
|
$767.69
|
| Cost And Expenses |
$16.30 M
|
$22.47 M
|
$17.40 M
|
$8.24 M
|
$4.73 M
|
$7.42 M
|
$7.70 M
|
$1.20 M
|
-$833.31
|
-$767.69
|
| Interest Income |
$914.00
|
$69.00 K
|
$314.00 K
|
$6.73 K
|
$102.00
|
$0.00
|
$32.80 K
|
$0.00
|
$0.00
|
$1.92
|
| Interest Expense |
$0.00
|
$69.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$60.00
|
$441.00
|
$0.18
|
$0.00
|
| Depreciation & Amortization |
$4.00 K
|
$38.00 K
|
$40.00 K
|
$7.89 K
|
$6.82 K
|
$9.70 K
|
$6.49 K
|
$1.44 K
|
$0.72
|
$762.00
|
| EBITDA |
-$16.30 M |
-$22.44 M |
-$17.15 M |
-$8.24 M |
-$4.72 M |
-$7.37 M |
-$7.66 M |
-$1.20 M |
-$828.39 |
-$3.77 |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$6.26 M
|
-$104.00 K
|
$106.00 K
|
-$32.07 K
|
$19.25 K
|
-$40.62 K
|
-$1.72 M
|
-$134.40 K
|
-$4.39
|
-$3.77
|
| Income Before Tax |
-$10.05 M
|
-$22.58 M
|
-$17.29 M
|
-$8.28 M
|
-$4.71 M
|
-$7.47 M
|
-$7.63 M
|
-$1.33 M
|
-$833.49
|
-$765.77
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$11.60 M
|
$69.00 K
|
-$106.00 K
|
$32.27 K
|
$19.25 K
|
$40.62 K
|
$60.00
|
$441.00
|
$0.00
|
-$3.77
|
| Net Income |
$1.55 M
|
-$22.65 M
|
-$17.18 M
|
-$8.31 M
|
-$4.71 M
|
-$7.47 M
|
-$7.63 M
|
-$1.33 M
|
-$833.49
|
-$765.77
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
0.0239 |
-0.42 |
-0.35 |
-0.26 |
-0.18 |
-0.31 |
-0.45 |
-0.0834 |
-0.0534 |
-0.0491 |
| EPS Diluted |
0.0239 |
-0.42 |
-0.35 |
-0.26 |
-0.18 |
-0.31 |
-0.45 |
-0.0834 |
-0.0534 |
-0.0491 |
| Weighted Average Shares Out |
$64.74 M
|
$54.29 M
|
$49.66 M
|
$31.90 M
|
$25.67 M
|
$24.37 M
|
$16.91 M
|
$16.00 M
|
$15.60 K
|
$15.60 K
|
| Weighted Average Shares Out Diluted |
$64.74 M
|
$54.29 M
|
$49.66 M
|
$31.90 M
|
$25.67 M
|
$24.37 M
|
$16.91 M
|
$16.00 M
|
$15.60 K
|
$15.60 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
